Document is current
Any future updates will be listed below
-
Authors
Wang, Yupeng https://orcid.org/0009-0009-4217-6569
Wilfahrt, Drew
Jonker, Patrick
Lontos, Konstantinos
Cai, Chufan
Cameron, Benjamin
Xie, Bingxian
Peralta, Ronal M.
Schoedel, Emerson R. https://orcid.org/0009-0004-3841-0555
Gunn, William G. https://orcid.org/0009-0007-9070-7550
AminiTabrizi, Roya
Shah, Hardik https://orcid.org/0000-0001-8408-5686
Rivadeneira, Dayana B. https://orcid.org/0000-0001-9483-7036
Muir, Alexander https://orcid.org/0000-0003-3811-3054
Delgoffe, Greg M. https://orcid.org/0000-0002-2957-8135
- License Information
-
More Information
Article History
Received: 31 May 2024
Accepted: 4 March 2025
First Online: 21 April 2025
Competing interests
: G.M.D. declares competing financial interests and has submitted patents targeting exhausted T cells that are licensed or pending and is entitled to a share in net income generated from licensing of these patent rights for commercial development. G.M.D. consults for and/or is on the scientific advisory board of BlueSphere Bio, Novasenta, Xyphos and Kalivir Immunotherapeutics; has grants from Novasenta, Astellas, RemplirBio and Kalivir; and owns stock in Novasenta, BlueSphere Bio and RemplirBio. The other authors declare no competing interests.
